Authors of a new study presented at the 2019 ACR/ARP Annual Meeting assessed whether high-dimensional flow cytometry profiling can distinguish patients with psoriasis and patients with PsA.
While anti-tumor necrosis factor (TNF) inhibitors are effective treatments for patients with several inflammatory diseases, they may be associated with new onset psoriatic eruptions or paradoxical worsening...
Erin E. Boh, MD, PhD, discussed special populations that could benefit from anti-tumor necrosis factor inhibitors for psoriasis at the 2019 AAD Summer Meeting.
Researchers of the PsABio study evaluated the connection between body mass index and psoriatic arthritis disease activity, disability, and patient-reported outcomes among individuals with psoriatic...
In April 2019, the FDA approved a new topical therapy for psoriasis—Duobrii (halobetasol propionate tazarotene 0.01%/0.045% lotion). According to Lawrence Green, MD, this new therapy appears to be...
In a new study to be presented at the Annual European Congress of Rheumatology, researchers compared disease activity, quality of life, and work productivity of more than 2500 individuals with PsA, with and...
The National Psoriasis Foundation’s medical board recommends the recombinant zoster vaccine for certain patients with psoriasis or psoriatic arthritis.
About 34% of the US population has metabolic syndrome. Because of this, authors of a study presented at ACC.19 measured the impact time-restricted eating could have on weight loss and metabolism among...
Researchers recently aimed to explore the potential relationship between hyperhidrosis and mental health conditions including ADD, depression, and anxiety. The findings were presented at the 2019 AAD Annual...
